Peppermint oil is one of the few supplements that turns up in gastroenterology guidelines. Capsules of the oil have been tested in people with irritable bowel syndrome (IBS) since the late 1970s, and it is routinely described as the best-supported natural option for cramping and abdominal pain. Part of that reputation is earned. Part of it is several years out of date.
The evidence has two halves. Pooled analyses of mostly small, older trials favor enteric-coated capsules (coated to pass through the stomach before releasing the oil) over placebo for a few weeks. But the two largest recent adult trials, and the largest trial in children, found no significant difference from placebo on their main measures, and the most recent pooled analysis (meta-analysis) devoted to peppermint oil rates the certainty of the evidence as very low.
The short version
- The pooled evidence favors it, at very low certainty. A 2022 meta-analysis of 10 trials in 1,030 adults found that people taking peppermint oil capsules were more likely than people on placebo to report improvement in overall symptoms and in abdominal pain. Its authors rated the certainty of that evidence as very low.
- The two largest recent adult trials missed their main endpoints. An eight-week Dutch trial (189 adults analyzed) and a six-week US trial funded by the National Institutes of Health (133 adults) found no significant difference from placebo on their main measures. Neither was large enough to rule out a modest benefit.
- Guidelines suggest it, weakly. American, British and Canadian gastroenterology guidelines make conditional or weak suggestions based on low or very low quality evidence, and all three were written before the 2021 US trial and before the 2022 meta-analysis that rated the evidence very low.
- The trials tested coated capsules taken every day. We found no trial of peppermint tea or as-needed use for IBS, and none designed to test uncoated oil. Capsules are swallowed whole, never chewed.
- Heartburn is the common tradeoff. In pooled trials, reflux symptoms were about 1.7 times as likely with peppermint oil as with placebo. Anyone with reflux, or taking an acid-reducing medicine, should check with a clinician or pharmacist first.
- Not one for children, pregnancy or breastfeeding without a clinician. The largest trial in children (228 children, 2026) found no significant difference from placebo, and safety in pregnancy and breastfeeding has not been established.
- IBS is a diagnosis, not a guess. Blood in the stool, black stools, unintended weight loss or symptoms that start later in life need a clinician, not a capsule.
Why peppermint oil has its reputation
IBS is defined by recurring abdominal pain that is tied to bowel movements, along with a change in how often people go or in what the stool looks like. It is diagnosed by a clinician from the pattern of symptoms, a physical exam and a few tests, once warning signs have been ruled out, and the available treatments help some people and not others. Into that gap steps an inexpensive capsule sold without a prescription, backed by decades of small trials and mentioned by name in specialist guidelines. It is easy to see why peppermint oil became the default suggestion.
The marketing goes further than the guidelines do. Brand pages use phrases such as clinically shown, number one gastroenterologist recommended and starts working in as little as 24 hours, and articles still repeat that peppermint oil ranked first among IBS treatments. Most of those lines trace back to a published study. The number one line is narrower than it sounds: the brand's own footnote limits it to gastroenterologists who already recommend peppermint oil. The useful question is how much weight each study can bear, and what happened when larger trials were run.
How peppermint oil is thought to work
Peppermint oil comes from the peppermint plant, Mentha piperita, and its main component is menthol, which makes up roughly a third to a half of the oil. The leading explanation for its effect on the gut is simple: menthol relaxes smooth muscle. In laboratory studies on strips of human colon and small intestine removed during surgery, menthol and peppermint oil weakened muscle contractions by blocking the calcium channels that muscle cells need in order to contract. In living people, a 2025 meta-analysis of 14 randomized trials found that menthol applied to the gut wall during endoscopy quieted its contractions more often than placebo did.
That is good evidence that menthol and peppermint oil relax gut muscle on direct contact. It is weaker evidence for a capsule that is swallowed. The same review describes three trials of peppermint oil capsules swallowed before colonoscopy: one reported less spasm than placebo, and two, including a 2021 trial of IBgard, a US brand of peppermint oil capsule, found no significant difference in spasm scores. Nor is it proof that muscle relaxation is why some trial participants reported less pain, which remains an inference. A second idea, that menthol acts on a cold-sensing receptor on the gut's pain nerves, rests on laboratory and biopsy studies, and the one capsule built to exploit it, which released the oil further down the gut, showed no significant difference from placebo on either main endpoint in the Dutch trial described below. That trial's authors still considered an effect on the gut's sensory nerves possible. The mechanism is not settled.
The same muscle-relaxing action explains the main side effect. Peppermint oil also relaxes the valve between the esophagus and the stomach, which lets stomach contents travel upward. That is the reason the trials used coated capsules, and the reason heartburn runs through everything that follows.
The evidence at a glance
| The claim | What was tested | Best evidence | Our read |
|---|---|---|---|
| Capsules improve overall symptoms and abdominal pain | Enteric-coated or delayed-release capsules, about 540 to 900 mg a day, for 4 to 12 weeks, in adults | A 2022 meta-analysis of 10 trials in 1,030 adults. Overall symptoms: relative risk of not improving 0.65 (0.43 to 0.98). Pain: 0.76 (0.62 to 0.93). The authors rate the certainty very low; in the low-bias trials alone the overall result was not significant and pain was 0.78 (0.61 to 0.99) | Favors peppermint oil on paper, fragile underneath. Pain is the steadier signal |
| The largest recent trials confirm it | A Dutch trial: 182 mg three times daily, 8 weeks, 189 adults. A US trial: 180 mg three times daily, 6 weeks, 133 adults (46 on peppermint oil) | Dutch trial: pain responders 46.8% vs 34.4% on placebo (P = .170); overall relief 9.7% vs 4.7% (P = .317). US trial: symptom score improved 90.8 points vs 100.3 on placebo (P = 0.97) | Not confirmed. Neither trial was large enough to rule out a modest benefit |
| Guidelines recommend it, and it ranked first | Guideline panels, and a network meta-analysis of 51 trials | American College of Gastroenterology 2021: conditional, low quality. British Society of Gastroenterology 2021: weak, very low. Canada 2019: conditional, low. American Gastroenterological Association 2022: no peppermint-specific advice. Network analysis: first for overall symptoms, third for pain, no significant differences between treatments | Weak suggestions, written before the 2021 US trial and the 2022 meta-analysis. Ranked first is not proven best |
| A US brand is clinically shown, and fast | IBgard, 180 mg three times daily, 4 weeks, 72 adults | Symptom score down 40% vs 24.3% on placebo (P = 0.0246); at 24 hours, 19.6% vs 10.3%. Funded by the maker, with company-affiliated authors, a scale not previously validated, and no independent repeat that we could find | One small sponsor-run trial. It does not transfer to other brands |
| It is gentle, and the coating stops heartburn | Side effect reports from the same trials | 2022 meta-analysis: any side effect 17.1% vs 12.1%, relative risk 1.57 (1.04 to 2.37); reflux symptoms relative risk 1.67 (1.18 to 2.38). Dutch trial daily diaries: heartburn 50.0% vs 28.1%; no serious events | Mostly mild, but real. Coated capsules still raised reflux |
| It works for children | 182 mg capsules two or three times daily, 8 weeks, 228 children aged 8 to 18 (2026); two smaller trials (2001 and 2015) | 2026 trial: pain cut by at least 30% in 44.0% vs 37.3% on placebo (P = .44). 2001 trial: 75% improved on peppermint oil, with no placebo figure in the abstract; a later guideline re-analysis was not significant. 2015 trial: pain improved more than on placebo, with only 88 of 120 children analyzed | The largest trial does not support it |
| Tea, mints, as-needed or long-term use work the same | No trial of tea found; open-label mints in children; adult trials ran 2 to 8 weeks (one ran 12 weeks) with regular daily dosing | Mints: pain cut by at least 30% in 38.7% vs 37.3% on placebo. Dutch trial: no significant difference from placebo during 6 months after stopping. The American College of Gastroenterology guideline notes that none of the studies it reviewed tested as-needed use | Mints were not superior to placebo in one open-label arm in children. For tea, as-needed use and use beyond 12 weeks, we found no trials |
These summaries describe research in people diagnosed with irritable bowel syndrome. They are not claims about what a supplement does, and percentages from different trials were measured in different ways, so they cannot be compared with each other. A relative risk below 1 means the outcome was less common with peppermint oil than with placebo, and above 1 more common. The range in parentheses after it is the 95% confidence interval. A P value above .05, such as .170 or 0.97, means the difference was not statistically significant.
The pooled analyses: favorable on paper
The most recent meta-analysis devoted to peppermint oil was published in 2022 and pooled 10 randomized trials in 1,030 adults. For overall symptoms, 55.9% of people taking peppermint oil reported no improvement, compared with 70.4% of people on placebo. Pooled across the trials, the relative risk of not improving was 0.65 (95% confidence interval 0.43 to 0.98). A relative risk below 1 means fewer people on peppermint oil than on placebo went without improvement, and because the whole interval sits below 1, the difference counts as statistically significant. (The pooled figure weights each trial separately, so it is not simply one percentage divided by the other.) For abdominal pain, the figures were 47.3% and 59.7%, with a pooled relative risk of 0.76 (0.62 to 0.93). On those numbers, peppermint oil beat placebo on both measures.
The same paper explains why its authors rated the certainty of the evidence as very low. Only 3 of the 10 trials were judged to be at low risk of bias. When the analysis was limited to those, the overall-symptom result was no longer statistically significant (relative risk 0.77, confidence interval 0.28 to 2.08), and the pain result only just held (0.78, confidence interval 0.61 to 0.99). The trials disagreed with each other far more than chance would explain, and there were statistical signs that small unfavorable studies may be missing from the published record. Blinding is also a problem particular to peppermint: the smell, the taste and the minty belching can tell participants which group they are in.
Earlier meta-analyses reported larger effects. One from 2014 pooled 9 studies in 726 patients, and one from 2019 pooled 12 trials in 835 patients and is the analysis the American College of Gastroenterology guideline leaned on. Both were completed before the two largest recent trials existed, so their estimates rest on the small, older studies alone.
The line quoted most often comes from a 2020 network meta-analysis, a method that ranks treatments against each other even where no trial compared them head to head. It covered 51 trials and 4,644 patients and compared fiber, antispasmodic drugs, peppermint oil and gut-brain neuromodulators (a group that includes some antidepressants). Peppermint oil capsules ranked first for overall symptoms. The fine print matters: peppermint oil ranked third for abdominal pain, there were no significant differences between the active treatments, only 13 of the 51 trials were at low risk of bias, and the analysis was published before the 2021 US trial. Ranked first is a position on a list, not proof that something works best.
One more piece of context: people with IBS improve a great deal on placebo. Across 73 drug trials, a 2021 meta-analysis put the pooled placebo response at 27.3% for overall improvement and 34.4% for abdominal pain. That is why feeling better after starting a capsule, however real the improvement, cannot settle whether the capsule caused it, and why the placebo-controlled trials below carry the weight.
The largest recent trials, and one maker-funded success
The Dutch trial (2020). The largest adult trial randomized 190 people with IBS at four Dutch hospitals and analyzed 189. For eight weeks they took a standard 182 mg capsule that releases in the small intestine, three times a day, or an experimental capsule designed to release the oil later, or placebo. The first of its two main endpoints (the results a trial names in advance as its test) was the kind drug regulators ask for: at least a 30% drop in worst abdominal pain in at least four of the eight weeks. It was reached by 46.8% of the standard-capsule group and 34.4% of the placebo group, a difference that was not statistically significant (P = .170). In the later-release group the figure was 41.3%, also not significantly different from placebo (P = .385). The second main endpoint, overall relief, was reached by 9.7% of the standard-capsule group and 4.7% of the placebo group (P = .317).
Some secondary measures, including average pain scores, did favor the standard capsule, and the authors label those findings exploratory. During the six months after treatment stopped there was no significant difference from placebo. The trial was funded by a Dutch government research grant. The capsules were supplied in kind by their manufacturer, which also gave two of the authors an unrestricted research grant and had the opportunity to review the manuscript; the authors state that the design, analysis and decision to publish were theirs. The trial had been designed to detect a gap of 30 percentage points and found one of about 12, so it cannot rule out a modest benefit.
The US trial (2021). A trial at a Boston hospital, funded by the National Institutes of Health, randomized 133 adults: 46 to an enteric-coated peppermint oil softgel, 180 mg three times a day, and 87 to placebo, for six weeks. On a widely used symptom severity score, the peppermint oil group improved by 90.8 points and the placebo group by 100.3 points (P = 0.97), and there was no significant difference on any secondary measure. Both groups got better. Peppermint oil did not get people further than placebo did. This trial has real limits: the peppermint oil group was a small arm added to a larger study of placebo effects, and 30 of its 46 participants finished, compared with 71 of 87 on placebo. The trial's published protocol names the softgel as Pepogest, a product still sold in the United States.
The maker-funded trial (2016). The trial behind the clinically shown and 24-hour marketing lines enrolled 72 adults with mixed or diarrhea-predominant IBS at four US sites. For four weeks they took IBgard, a capsule of coated microspheres, at 180 mg three times a day, or placebo. A total symptom score fell by 40% on peppermint oil and by 24.3% on placebo (P = 0.0246), and a difference was already measurable at 24 hours (19.6% versus 10.3%). That is a positive result, and it comes with caveats: the trial was funded by the product's maker, all three authors were company officers or consultants, the symptom scale had not been previously validated, people with constipation-predominant IBS were excluded, and as far as we can find the result has not been repeated independently.
The older trials. The pooled estimates lean on small studies from the 1990s and 2000s, mostly of capsules sold in Europe. In a 1997 trial of 110 patients, pain eased in 79% of those on peppermint oil and 43% of those on placebo after one month. A 2007 Italian trial of 57 patients reported that 75% versus 38% had their total symptom score fall by more than half at four weeks. A 2010 trial of 90 outpatients reported 14 people free of abdominal pain at eight weeks on peppermint oil and 6 on placebo, though a third of participants did not finish. Not every early trial pointed the same way: a 2005 review counted 12 placebo-controlled trials, of which 8 showed statistically significant effects in favor of peppermint oil, and one small 1986 crossover trial reported that it did not relieve pain. The favorable results are why the reputation exists. They also come from the kind of small, short trials that larger studies often fail to match.
How to read all of this. A missed main endpoint is not proof of no effect. The 2022 meta-analysis included both the Dutch trial and the US trial, and its pooled estimate still favored peppermint oil, most consistently for pain. The fair summary is that a modest effect on abdominal pain over a few weeks is possible, the large effect seen in the older trials has not been matched in the bigger ones, and nobody should be told this is a proven fix.
What the guidelines actually say
Peppermint oil's place in the guidelines is real, and weaker than it is usually reported.
- American College of Gastroenterology, 2021: "We suggest the use of peppermint to provide relief of global IBS symptoms." This is a conditional recommendation based on low quality evidence, and the guideline adds that only a small number of the peppermint oil supplements on sale have been rigorously tested.
- British Society of Gastroenterology, 2021: peppermint oil "may be an effective treatment" for overall symptoms and abdominal pain, with reflux named as a common side effect. The recommendation is weak and the quality of evidence very low. The guideline also cautions that results from the specific products tested "cannot be extrapolated to other formulations."
- Canadian Association of Gastroenterology, 2019: suggests offering peppermint oil to improve IBS symptoms, a conditional recommendation based on low quality evidence, with concerns noted about blinding.
- American Gastroenterological Association, 2022: makes no peppermint-specific recommendation. Its guideline for IBS with diarrhea gives a conditional suggestion for antispasmodics as a class, on low certainty evidence, and names peppermint oil as one of three studied antispasmodics available in the United States.
The three guidelines above that suggest peppermint oil were all written before the 2021 US trial and before the 2022 meta-analysis that rated the evidence very low. Two of them did have the Dutch trial in view: the American College of Gastroenterology guideline describes its missed endpoint alongside the secondary results that favored the standard capsule, and the British guideline's pooled estimate includes it. A conditional or weak recommendation is guideline language for something that may be reasonable to try, where the evidence is uncertain and the decision depends on the individual patient.
Regulation differs by country, which adds to the confusion. The European Medicines Agency's herbal monograph for peppermint oil, its official summary of accepted uses, doses and cautions, classes coated capsules as a "well-established use" herbal medicine, and in the United Kingdom a 0.2 mL capsule is sold as a licensed medicine. Those are foreign frameworks. In the United States the capsules are dietary supplements, which cannot be marketed to treat a disease. Older articles describe one US brand, IBgard, as a medical food for IBS, and Internet Archive captures show the brand's own website saying so as late as January 2022. The current box is labeled a dietary supplement and does not mention IBS.
Why the capsule matters: coatings, tea, mints and drops
Nine of the ten trials in the 2022 meta-analysis used capsules built to release the oil in the small intestine, and the tenth did not report its formulation. The coating is there to carry the oil past the stomach, because oil released early can irritate the esophagus and relax the valve that keeps stomach contents down. The European monograph tells people to swallow the capsules whole for that reason, and in one early trial a participant developed heartburn after chewing them. For more on how these coatings work, see our guide to enteric coating and delayed release.
The coating is meant to limit heartburn, and it does not prevent it: in the Dutch trial, people taking the standard coated capsule still reported heartburn far more often than people on placebo. We also found no IBS trial that compared symptoms or side effects between the coatings of the brands on sale, or between a coated capsule and an uncoated one, so brand claims that a particular coating is gentler or works better appear to be untested. The Dutch trial did compare two release designs head to head, and it found a trade, not an improvement. With the experimental late-release capsule, heartburn was reported by 36.5% (50.0% on the standard capsule, 28.1% on placebo) and belching by 19.0% (45.2% and 23.4%). But that capsule was not significantly different from placebo on pain, and 61.9% of that group reported altered anal sensation or urethral sensitivity at least once, compared with 35.5% on the standard capsule and 14.1% on placebo. The trial's authors concluded that the findings did not support developing it further.
What about everything that is not a coated capsule?
- Peppermint tea. A 2006 review noted that clinical trials of peppermint tea were absent, and we found no IBS trial of tea since. Tea may be a pleasant drink, but the capsule results cannot be assumed to carry over to it.
- Mints and candies. Tested once, in an open-label arm of the 2026 children's trial, meaning families knew what they were taking: 38.7% responded, compared with 37.3% on placebo capsules.
- Liquid oil, drops and uncoated softgels. We found no IBS trial designed to test them (one trial in the 2022 meta-analysis did not report what form it used), and oil released in the stomach is the situation the coating exists to avoid.
- As-needed use. The American College of Gastroenterology guideline notes that every study it reviewed used regular daily dosing, and that none tested taking peppermint oil only when symptoms flare.
Capsules that combine peppermint oil with caraway oil were studied mainly for functional dyspepsia, which means discomfort in the upper abdomen such as fullness after meals. A 2023 Cochrane review concluded that the combination probably improves overall dyspepsia symptoms at four weeks, based on two trials in 210 participants. For IBS, a 2023 review sponsored by the combination's maker found only one randomized trial, in 200 patients and reported only as a conference abstract, and its results did not reach statistical significance. The US product FDgard is different again: it contains caraway oil and L-menthol rather than whole peppermint oil, and the one placebo-controlled trial of it that we found, funded by the maker in 95 people, reported a significant difference from placebo in one group of symptoms at 24 hours and no significant difference in overall symptom scores at two and four weeks. None of the dyspepsia findings is evidence about IBS.
Dose, timing and how long the trials ran
Most trials used one capsule containing about 0.2 mL of peppermint oil, described in the papers as 180 to 187 mg, three times a day, for a total of roughly 540 to 560 mg a day. The Italian product was given as two 225 mg capsules twice a day. The European monograph describes a range of 0.2 to 0.4 mL per dose, two or three times a day.
Capsules were taken before food, usually about 30 minutes before meals, and swallowed whole. The Dutch trial stepped the dose up over the first week specifically to limit heartburn and belching.
Duration is the weakest part of the evidence. The adult trials in the 2022 meta-analysis lasted four to eight weeks, apart from one that ran 12 weeks, and some older trials lasted only two or three weeks. The European monograph limits a course to three months. What happens afterward is unclear: in one trial the symptom score was still below its starting point four weeks after stopping, in another pain rose again within two weeks, and in the Dutch trial there was no significant difference from placebo over six months of follow-up. Nothing supports open-ended daily use. These are descriptions of what studies did, not dosing advice.
Side effects, interactions and who should be careful
Peppermint oil has a reputation for being gentle, and in trials most side effects were mild. They were also more common than on placebo. In the 2022 meta-analysis, 17.1% of people taking peppermint oil reported a side effect of any kind, compared with 12.1% on placebo (relative risk 1.57, confidence interval 1.04 to 2.37), and reflux symptoms were about 1.7 times as likely (relative risk 1.67, confidence interval 1.18 to 2.38). Earlier meta-analyses disagreed on this point: one from 2014 found side effects significantly more likely with peppermint oil, and one from 2019 found the difference not statistically significant. Both predate the Dutch trial.
The Dutch trial gives the most detailed picture, because participants recorded symptoms in a daily diary. Over eight weeks, heartburn was reported at least once by 50.0% of people on the standard coated capsule and 28.1% on placebo, and belching by 45.2% and 23.4%. Peppermint-scented stools were noticed by 29.0% (1.6% on placebo), and 35.5% reported altered anal sensation or urethral sensitivity (14.1% on placebo). Three of 62 people on the standard capsule stopped because of side effects, compared with 1 of 64 on placebo, and there were no serious adverse events. Diary numbers run much higher than the pooled figures because people were asked every day, which is why even the placebo group reported so much heartburn. The two sets of numbers should not be compared directly.
- Heartburn, reflux or a hiatal hernia. The European monograph says people who already have heartburn or a hiatal hernia sometimes get worse on peppermint oil, and should stop if that happens. Our guide to supplements and acid reflux covers that side of the problem.
- Antacids and acid-reducing medicines. The same monograph warns that antacids taken at the same time, H2 blockers and proton pump inhibitors may dissolve the coating early. This is a precaution based on how the coating works, and we found no clinical study that tested it. Ask a pharmacist.
- Liver disease, gallstones or bile duct problems. The European monograph lists these as reasons not to take the capsules.
- Pregnancy and breastfeeding. Safety has not been established, and the European monograph says use is not recommended. Menthol passes into breast milk in small amounts.
- Children. Not recommended under age 8 in Europe, and the largest trial found no significant difference from placebo. See the next section.
- Prescription medicines. In one small study of 12 healthy volunteers, a single 600 mg dose of peppermint oil raised blood levels of the blood pressure drug felodipine to about 140% of the level seen with water. A second study, of menthol alone, found essentially no change. The interaction is possible, not established. Ask a pharmacist if you take regular medication.
- Allergies. Allergic reactions to menthol are reported. Some softgels contain soy, and one capsule sold in the United Kingdom contains peanut oil, so read the inactive ingredients.
- Never chew the capsules. Chewing releases the oil before it gets past the stomach.
IBS should be diagnosed by a clinician, not assumed. The American College of Gastroenterology guideline lists alarm features that call for a medical evaluation: blood in the stool, black tarry stools, unintended weight loss, symptoms that begin at an older age, and a family history of inflammatory bowel disease, colon cancer or other significant gastrointestinal disease. New or changing symptoms are a reason to go back, not a reason to add a supplement.
Children and teenagers: what the largest trial found
Until 2026, the case for peppermint oil in children rested on two small trials. In the first, from 2001, 42 children took capsules or placebo for two weeks, and 75% of the peppermint oil group reported less severe pain. The abstract gives no placebo figure, and when a 2025 pediatric guideline re-analyzed the trial, the difference between groups (60% versus 36%) was not statistically significant. The second, from 2015, assigned 120 children aged 4 to 13 with functional abdominal pain to peppermint oil capsules, a synbiotic (a probiotic combined with a prebiotic fiber) or placebo for one month, and reported greater improvement in pain duration, frequency and severity on peppermint oil than on placebo. Only the 88 children who finished the month were analyzed. The 2025 guideline, from the European and North American pediatric gastroenterology societies, said that enteric-coated capsules "may be suggested," a conditional recommendation on low certainty evidence from those two small studies.
Then came a much larger test. A 2026 trial at 13 Dutch hospitals randomized 228 children aged 8 to 18 with IBS or functional abdominal pain to 182 mg peppermint oil capsules two or three times a day, to peppermint candies, or to placebo, for eight weeks. A pain reduction of at least 30% was reached by 44.0% on peppermint oil and 37.3% on placebo (odds ratio 1.33, 97.5% confidence interval 0.58 to 3.09, P = .44). The placebo capsules even contained a trace of peppermint oil to protect the blinding. The authors concluded that neither the capsules nor the candies were superior to placebo.
The guideline predates that trial. Taken together, there is no good reason to give a child peppermint oil capsules without a pediatrician's involvement.
If you are going to buy one
If, after all that and a conversation with a clinician, an adult decides to try a capsule, these are three widely sold enteric-coated options. The first two were each the test product in one of the placebo-controlled trials described above, and they appear in the order those trials were published. We found no published trial of the third. That order is not a ranking of how well each performed: the trial section above has the results. We found no trial that compared these products with each other. The cards give label facts as read on October 11, 2026.
Prices, formulas and inactive ingredients change, so check the current label. For all three: adults only, swallow whole and never chew, and stop if heartburn appears or gets worse. Do not use during pregnancy or breastfeeding unless a clinician advises it. If you take an acid-reducing medicine or any regular prescription, ask a pharmacist first.
Frequently asked questions
Does peppermint oil help with IBS?
The evidence is mixed, and less certain than peppermint oil's reputation suggests. A 2022 meta-analysis of 10 trials in 1,030 adults found that people taking enteric-coated peppermint oil capsules were more likely than people on placebo to report improvement in overall symptoms and in abdominal pain, and its authors rated the certainty of that evidence as very low. That analysis included the two largest recent adult trials, each of which found no significant difference from placebo on its main measures. IBS needs a clinician's diagnosis, and peppermint oil is something to raise with that clinician, not a substitute for care. Blood in the stool, black stools, unintended weight loss or symptoms that begin at an older age are alarm features in the American College of Gastroenterology guideline and need a medical evaluation.
How much peppermint oil did the IBS trials use?
Most trials used one enteric-coated capsule containing about 0.2 mL of oil, described in the papers as 180 to 187 mg, three times a day. Capsules were taken before food, usually about 30 minutes before meals, and swallowed whole. One trial raised the dose gradually over the first week to limit heartburn and belching. This describes what studies used, not a dose recommendation.
How long does peppermint oil take to work?
Nobody knows precisely. Most trials measured results after 4 to 8 weeks of taking capsules three times a day. The claim that it starts working within 24 hours comes from a single four-week trial of 72 people that was funded by the product's maker, and as far as we can find that early result has not been repeated independently. We found no trial that tested taking peppermint oil only when symptoms flare.
Does peppermint tea work the same way as the capsules?
There is no trial evidence that it does. Nine of the ten trials in the 2022 meta-analysis used capsules built to release the oil in the small intestine, and the tenth did not report its formulation. A 2006 review noted that clinical trials of peppermint tea were absent, and we found no IBS trial designed to test tea, liquid oil or uncoated capsules since. Peppermint candies were tested once, in an open-label arm of a 2026 trial in children, and were not superior to placebo. Tea may be a pleasant drink, but the capsule results cannot be assumed to carry over to it.
Can peppermint oil cause heartburn?
Yes. It is the most common tradeoff. In the 2022 meta-analysis, reflux symptoms were about 1.7 times as likely with peppermint oil as with placebo. In the largest adult trial, which asked participants about symptoms every day, 50.0% of those taking the standard coated capsule reported heartburn at least once in eight weeks, compared with 28.1% on placebo. Peppermint oil relaxes the muscular valve at the top of the stomach. Coated capsules are meant to limit this, but they do not remove it, and chewing a capsule releases the oil early. The European monograph for peppermint oil capsules says to stop if heartburn gets worse.
Can you take peppermint oil with antacids or acid reducers?
Ask a pharmacist first. The European monograph for coated peppermint oil capsules warns that antacids taken at the same time, and acid-reducing medicines such as H2 blockers and proton pump inhibitors, may dissolve the coating early, which would release the oil in the stomach. That warning is a precaution based on how the coating works, and we found no clinical study that tested it. The same monograph notes that people who already have heartburn sometimes find it gets worse on peppermint oil.
Is peppermint oil safe for children, or during pregnancy?
Neither is a do-it-yourself situation. The largest trial in children, published in 2026 with 228 participants aged 8 to 18, found no significant difference between peppermint oil capsules and placebo for abdominal pain, and the European monograph for the capsules does not recommend them under age 8 because of a lack of data. Safety in pregnancy and breastfeeding has not been established, and the same monograph says use is not recommended. Menthol passes into breast milk in small amounts. These are decisions for a pediatrician or obstetric clinician.
Can you take peppermint oil long term?
There is no good evidence either way. The adult trials in the 2022 meta-analysis lasted 4 to 8 weeks, apart from one that ran 12 weeks, and some older trials were shorter. The European monograph for peppermint oil capsules limits a course to three months. In the largest adult trial, there was no significant difference from placebo during the six months after people stopped. Ongoing symptoms are a reason to go back to a clinician, not to keep extending a supplement.
The bottom line
Peppermint oil capsules are among the better-studied supplements for irritable bowel syndrome, and the evidence is weaker than the reputation. Pooled analyses of mostly small, older trials favor enteric-coated capsules over placebo for a few weeks, most consistently for abdominal pain. The most recent meta-analysis devoted to peppermint oil rates that evidence as very low certainty, and the two largest recent adult trials and the largest trial in children found no significant difference from placebo on their main measures. The guidelines that suggest it do so weakly, and the adult ones were written before the US trial and the 2022 meta-analysis. Heartburn is the common tradeoff, the trials tested coated capsules taken daily, mostly for four to eight weeks, and we found no trial evidence on tea, on as-needed use, or on use beyond 12 weeks. For an adult with a diagnosis, it is a reasonable short-term option to raise with a clinician. It is not a proven fix, and it is not a way to avoid getting persistent symptoms checked. For the other options people ask about, see our guides to probiotic strains for IBS and fiber supplements, and the IBS supplement hub.